1. Home
  2. ACRS vs SOPH Comparison

ACRS vs SOPH Comparison

Compare ACRS & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.45

Market Cap

529.9M

Sector

Health Care

ML Signal

N/A

Logo SOPHiA GENETICS SA

SOPH

SOPHiA GENETICS SA

N/A

Current Price

$6.22

Market Cap

462.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
SOPH
Founded
2012
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.9M
462.3M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
ACRS
SOPH
Price
$3.45
$6.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
5
Target Price
★ $9.82
$9.75
AVG Volume (30 Days)
★ 2.6M
666.6K
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.01
N/A
EPS
N/A
★ N/A
Revenue
★ $1,683,000.00
N/A
Revenue This Year
N/A
$23.68
Revenue Next Year
N/A
$24.29
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.46
$4.01
52 Week High
$6.60
$8.98

Technical Indicators

Market Signals
Indicator
ACRS
SOPH
Relative Strength Index (RSI) 39.18 37.40
Support Level $3.24 $4.58
Resistance Level $4.60 $6.54
Average True Range (ATR) 0.28 0.65
MACD -0.02 -0.09
Stochastic Oscillator 17.03 13.13

Price Performance

Historical Comparison
ACRS
SOPH

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

Share on Social Networks: